This multisite prospective clinical study is to investigate the relationship between seizure type and frequency with the BioEP result during ASM titration in newly diagnosed patients with epilepsy, and to assess the utility of BioEP as an early prognostic indicator of ASM efficacy
Adult (age 18 and above) presenting with first suspected seizure(s).
Able to give informed consent.
Patient has received an initial epilepsy diagnosis.
Patient accepts decision to commence ASM.
Participants unable to tolerate an EEG test so no EEG data were gathered.
Participants with a known hepatic/renal encephalopathy.
Patient diagnosed with possible NEAD and epilepsy (dual diagnosis).
Participants taking part in another Clinical Trial of an Investigational Medicinal Product (CTIMP) (qualitative/observational studies are acceptable).
Neuronostics Ltd
Lead sponsor
Cornwall Partnership NHS Foundation Trust
Collaborator